company background image
SNGX logo

Soligenix NasdaqCM:SNGX Stock Report

Last Price

US$0.61

Market Cap

US$6.4m

7D

-17.2%

1Y

-71.8%

Updated

18 Mar, 2024

Data

Company Financials +

SNGX Stock Overview

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.

SNGX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Soligenix, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Soligenix
Historical stock prices
Current Share PriceUS$0.61
52 Week HighUS$4.20
52 Week LowUS$0.38
Beta1.83
1 Month Change-11.47%
3 Month Change5.35%
1 Year Change-71.76%
3 Year Change-97.64%
5 Year Change-95.85%
Change since IPO-99.97%

Recent News & Updates

Recent updates

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Soligenix announces $2.6M FDA grant to further study blood cancer candidate

Sep 06

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Sep 06
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M

Aug 12

Soligenix, SERB Pharma team up to develop therapy for ricin poisoning

Jul 25

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Apr 22
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Jan 03
Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Sep 17
Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Aug 30
Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

May 08
Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 16
What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Soligenix inks supply and distribution deal for SGX301 companion light device in cancer

Jan 07

Soligenix receives $1.5M grant advancing COVID-19 vaccine development

Dec 28

Soligenix's SGX942 flunks oral mucositis study in cancer patients, shares plummet 44%

Dec 22

Soligenix announces $20M strategic convertible debt financing agreement

Dec 16

Why Soligenix's (NASDAQ:SNGX) CEO Pay Matters

Nov 20
Why Soligenix's (NASDAQ:SNGX) CEO Pay Matters

Shareholder Returns

SNGXUS BiotechsUS Market
7D-17.2%-2.1%0.5%
1Y-71.8%9.7%29.0%

Return vs Industry: SNGX underperformed the US Biotechs industry which returned 10.4% over the past year.

Return vs Market: SNGX underperformed the US Market which returned 28.4% over the past year.

Price Volatility

Is SNGX's price volatile compared to industry and market?
SNGX volatility
SNGX Average Weekly Movement13.0%
Biotechs Industry Average Movement11.9%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: SNGX's share price has been volatile over the past 3 months.

Volatility Over Time: SNGX's weekly volatility has decreased from 25% to 13% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
198714Christopher Schaberhttps://www.soligenix.com

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer.

Soligenix, Inc. Fundamentals Summary

How do Soligenix's earnings and revenue compare to its market cap?
SNGX fundamental statistics
Market capUS$6.42m
Earnings (TTM)-US$6.14m
Revenue (TTM)US$839.36k

7.6x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SNGX income statement (TTM)
RevenueUS$839.36k
Cost of RevenueUS$742.05k
Gross ProfitUS$97.31k
Other ExpensesUS$6.24m
Earnings-US$6.14m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.58
Gross Margin11.59%
Net Profit Margin-731.60%
Debt/Equity Ratio129.3%

How did SNGX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.